logo
What Brands Should Know About Forthcoming Canadian, US PFAS Regulations

What Brands Should Know About Forthcoming Canadian, US PFAS Regulations

Yahoo30-06-2025
About 12,000 different chemicals make up the family of per- and polyfluoroalkyl substances, also known as PFAS. These 'forever chemicals' have innumerable uses across product categories like footwear, apparel and accessories.
They've also been linked to manifold risks to human health and the environment. Whether used as a part of a manufacturing process or as an additive in a finished product, PFAS has been found in groundwater, drinking water and different bodies of water accessible to humans. According to the U.S. Environmental Protection Agency (EPA), exposure may lead to reproductive effects and interference with hormones, developmental delays in children, certain cancers, and immune system damage.
More from Sourcing Journal
WTO to Intervene in Trade Disputes Between Canada and China
DHL Express Canada Seeks 'Anti-Scab' Law Exemption, Citing 'Essential' Services
DHL Express Canada Plans Temporary Shutdown on Stalled Labor Talks
With these issues as a backdrop, the Canadian Apparel Federation and Marten Law hosted a webinar Wednesday dedicated to understanding the recent governmental intervention when it comes to companies' use of PFAS.
James Pollack, who leads Marten Law's consumer products regulatory practice, laid out the legislative continuum when it comes to regulation. The first set of products that became the focus of PFAS bans were children's products, and the next tranche of prohibitions focused on cookware, with the idea that PFAS might move from cooking surfaces or packaging into food.
'What's interesting is the next set of products that became a focus for folks was textiles, including apparel and footwear. And I think part of it is this visceral sense of, 'Well, I'm putting it on my body. There must be some sort of dermal transmission,'' Pollack said. Research on this is still ongoing, with a number of universities Like Duke researching whether PFAS can be absorbed through the skin. Last year, a team of researchers at Environment International, a team of researchers released findings that PFAS can indeed permeate the skin's barrier and enter the bloodstream.
'There are a number of states that have started to regulate PFAS in apparel and textiles more broadly, and each of the states defines those subjects differently,' Pollack said. In Washington state, for example, intentionally added PFAS—which is added to a product to attain a technical effect, like waterproofing—is banned. But other states, like Vermont, have an expanded ban that covers all PFAS detectable within a product, even if it's unintentionally added as a result of a manufacturing process.
Manufacturing is becoming an increasingly studied part of the PFAS journey, as the chemicals might be used on machines as a lubricant or a surfactant to help a plastic mold release, for example.
According to Pollack, regulation may have outpaced science at this juncture, with a less-than-complete understanding of PFAS' risks or methods of transmission into the human body. Most believe that drinking water is the primary route of exposure, though there are studies about whether it might be inhaled as dust particles, for example. As such, clothing and products like carpets (which might release those particles) are being studied.
In California, key regulations include bans on intentionally added PFAS chemicals in textiles, cosmetics and food packaging. The rollout of the PFAS textile ban will come in waves, as stipulated by AB1817. On Jan. 1, total organic fluorine levels were limited to 100 ppm, and that number will drop to 50 ppm in 2027 (though apparel made for severe outdoor conditions has until 2028 to achieve compliance).
Meanwhile, Maine, Minnesota and New Mexico have also made aggressive moves to ban the use of PFAS, with the former being the first to implement a comprehensive ban on all non-essential uses (though it's considering a bill that would exempt fluoropolymer-coated cookware). Minnesota and New Mexico also have broad bans on intentionally added use of PFAS, though Minnesota is mulling exempting commercial and industrial products. The state is also implementing mandatory chemical reporting requirements for products currently offered for sale on store shelves on Jan. 1, 2026.
'Those states are implementing these broad bans, and they create limited exemptions for what are called currently 'unavoidable uses,' which you have to apply for,' Pollack said. 'You have to show that there's no viable alternative and that the use is helpful for… the functioning of society or health and wellness of people. So a relatively limited exemption possibility there.'
Isabel Carey, a senior associate with the firm who heads up its Toronto office, spoke to Canada's regulatory environment.
'In March, Environment Canada and Health Canada proposed adding PFAS chemicals as a class with a major note as toxic substances under the Canadian Environmental Protection Act,' she explained, noting that fluoropolymers—a major type of PFAS used in the textile and apparel industry—are excluded because of differences in how people are exposed to them and the hazards that they pose to human health.
Once the government's proposal to classify the chemicals as toxic substances is finalized, there's no immediate regulatory consequence, nor does the classification prohibit the use of PFAS in the Canadian economy. It simply authorizes the government to issue regulations targeting those substances.
According to Marten Law, the agencies further proposed phasing out PFAS use 'wherever feasible'—firstly, in firefighting foams, and then across a range of industries like textiles, food packaging, cosmetics and medical devices where they believe the chemicals can be replaced. During Phase Two of regulation, Canada will evaluate prohibiting PFAS use in industries where alternatives are not available, and where the chemicals aren't being used for the protection of human health, safety or the environment.
The agencies haven't proposed binding regulations to implement their plans, but have announced that implementing regulations will be developed beginning in 2027, Marten Law added.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Very high levels of toxic chemicals found in eco-friendly menstrual products, study says
Very high levels of toxic chemicals found in eco-friendly menstrual products, study says

Yahoo

timea day ago

  • Yahoo

Very high levels of toxic chemicals found in eco-friendly menstrual products, study says

Extremely high levels of toxic chemicals called PFAS (perfluoroalkyl and polyfluoroalkyl substances) have been found in a small sampling of reusable menstrual pads and panties, according to a new study. 'Whether we wear feminine hygiene products or not, we will all be exposed,' said senior study author Graham Peaslee, a professor of physics, chemistry and biochemistry at the University of Notre Dame in Indiana. 'Everything in the US ultimately goes into landfills, and with time these forever chemicals leach into our drinking water, our irrigation water and our food supply,' Peaslee said. Perfluoroalkyl and polyfluoroalkyl substances are called 'forever' chemicals because they fail to break down fully in the environment. Known endocrine disruptors, various types of PFAS have been linked to serious health problems such as cancer, obesity, high cholesterol, decreased fertility, low birth weight, accelerated puberty and hormone disruption, according to the EPA. The highest levels of contamination came from a type of 'neutral' PFAS that scientists know exist but have just recently been able to measure and more thoroughly test for harm, the study found. 'We typically measure a type of PFAS called ionic, which has a charge, and we can measure those down to parts per trillion which is a low exposure level,' Peaslee said. (An ionic charge is the positive or negative charge of an ion, an atom that has gained or lost electrons.) Newer technology is now allowing scientists to measure neutral PFAS — which have no charge. Some of the neutral versions are thought to be linked to the same health harms as the ionic versions, said Kathrin Schilling, an assistant professor of environmental science at Columbia University Irving Medical Center in New York City. She was not involved in the study. 'That's important because neutral PFAS tend to fly under the radar but can be more easily absorbed through the skin, or even mucous membranes like those in the vagina because they can more easily move through fatty tissues,' said Schilling via email. The new testing found an alarming amount of these neutral PFAS in some reusable period products, according to the study. 'When we measured the neutral PFAS there were much higher concentrations — not parts per trillion, not even parts per billion, but levels at parts per million — that's very, very high,' Peaslee said. What does that mean for the people using these products? 'The truth is, we still do not fully understand how they behave in the body or what long-term exposure might mean,' Schilling said. 'Neutral PFAS are not well studied, and there are no clear regulations for them yet.' Some PFAS added intentionally The study, published Tuesday in the journal Environmental Science and Technology Letters, analyzed 43 period underwear, eight reusable pads, four menstrual cups, three reusable incontinence underwear and one reusable incontinence pad — a total of 59 products. A separate part of the study also looked at tampons. 'We didn't provide manufacturer names in our study However, the majority were US manufacturers,' Peaslee said. 'We also looked at a few from South America, a couple from Australia and a couple from Europe. While the number of samples is small, we believe it was a representative snapshot.' In addition to measuring neutral and ionic PFAS, the study examined whether PFAS was found at low enough levels to indicate it was inadvertently added due to contamination during the manufacturing process. Researchers also searched for higher levels of PFAS that would indicate the chemicals were likely added on purpose. 'What's shocking is that we found 33% of period underwear and 25% of reusable pads had intentional PFAS use — meaning the chemicals had been put there, likely to keep the products from leaking,' Peaslee said. Many reusable materials were sourced from third-party suppliers in other countries, who may not be as aware of the dangers of PFAS as domestic manufacturers, he said. 'It did seem to be random — sometimes they put PFAS in the inside layer of material, sometimes on the outside, sometimes between the layers, all of which suggests they have no idea what they're doing,' Peaslee added. 'There's no labeling, so consumers have no clue because there's no way they can tell.' There were some encouraging findings, said lead author Alyssa Wicks, who conducted the research while a graduate student at Notre Dame. 'Only a subset of the products had high levels of PFAS present, which means that PFAS must not be essential in the manufacture of reusable feminine hygiene products,' said Wicks, now a postdoctoral assistant in the Nicholas School of the Environment at Duke University in Durham, North Carolia. 'Manufacturers should be able to make these textile products without chemicals of concern in them,' Wicks said in a statement. A growing number of teens and adults are looking for more eco-friendly choices at a time when scientists still know very little about how much PFAS and other chemicals are actually absorbed via vaginal tissue over time, Schilling said. 'That is a huge gap in our understanding, especially given how many people rely on these products monthly for years,' she said. 'While these findings might seem niche at first glance, they point to a broader need for research, regulation, and transparency around the materials used in all menstrual products.' For more CNN news and newsletters create an account at

Kaida BioPharma Participates in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference
Kaida BioPharma Participates in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference

Yahoo

timea day ago

  • Yahoo

Kaida BioPharma Participates in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference

– Video webcast now available on-demand FORT LAUDERDALE, FL, July 22, 2025 (GLOBE NEWSWIRE) -- Kaida BioPharma ('Kaida' or the 'Company'), an early-stage pharma company dedicated to advancing targeted anti-cancer therapies to address hormone-driven cancers affecting women, today announced Stella Vnook, PhD, Co-Founder of Kaida, participated in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference. For the event, Dr. Vnook dove deeper into her dedication to the Company, how she got to where she is today and provided insight into why she is so passionate about the Company's program in development. The on-demand video webcast is now available on About Kaida BioPharmaKaida BioPharma was founded on the research principles and clinical evidence of the therapeutic benefit of blocking the binding of prolactin (PRL), a multifunctional hormone, to its receptor (PRLR), given their roles as growth factors in tumor growth and proliferation. The Company's lead product candidate KAD101 is a growth hormone antagonist designed to selective and effectively block the tumoral PRL/PRLR axis which has been shown to induce programmed cell death (autophagy) in gynecologic tumors. The Company is collaborating closely with Dr. John Langenheim, professor at Thomas Jefferson University, and Dr. Anil Sood, professor and vice chair for translational research in the departments of gynecologic oncology and cancer biology at MD Anderson Cancer Center, who have both published extensive research on prolactin and its role as a growth factor in tumor growth and progression and the potential therapeutic benefit of KAD101. Kaida is dedicated to providing a new hope for patients with treatment-resistant gynecological cancers. The Company's mission is to develop innovative therapies that target the specific needs of those patients, offering a medical treatment that can make a significant difference. For more information, please visit ContactJenene ThomasChief Executive OfficerJTC Team, LLCT: 908.824.0775E: kaida@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Kaida BioPharma Participates in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference
Kaida BioPharma Participates in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference

Yahoo

timea day ago

  • Yahoo

Kaida BioPharma Participates in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference

– Video webcast now available on-demand FORT LAUDERDALE, FL, July 22, 2025 (GLOBE NEWSWIRE) -- Kaida BioPharma ('Kaida' or the 'Company'), an early-stage pharma company dedicated to advancing targeted anti-cancer therapies to address hormone-driven cancers affecting women, today announced Stella Vnook, PhD, Co-Founder of Kaida, participated in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference. For the event, Dr. Vnook dove deeper into her dedication to the Company, how she got to where she is today and provided insight into why she is so passionate about the Company's program in development. The on-demand video webcast is now available on About Kaida BioPharmaKaida BioPharma was founded on the research principles and clinical evidence of the therapeutic benefit of blocking the binding of prolactin (PRL), a multifunctional hormone, to its receptor (PRLR), given their roles as growth factors in tumor growth and proliferation. The Company's lead product candidate KAD101 is a growth hormone antagonist designed to selective and effectively block the tumoral PRL/PRLR axis which has been shown to induce programmed cell death (autophagy) in gynecologic tumors. The Company is collaborating closely with Dr. John Langenheim, professor at Thomas Jefferson University, and Dr. Anil Sood, professor and vice chair for translational research in the departments of gynecologic oncology and cancer biology at MD Anderson Cancer Center, who have both published extensive research on prolactin and its role as a growth factor in tumor growth and progression and the potential therapeutic benefit of KAD101. Kaida is dedicated to providing a new hope for patients with treatment-resistant gynecological cancers. The Company's mission is to develop innovative therapies that target the specific needs of those patients, offering a medical treatment that can make a significant difference. For more information, please visit ContactJenene ThomasChief Executive OfficerJTC Team, LLCT: 908.824.0775E: kaida@ Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store